ReviewTherapeutic advances in medical oncology2025

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer.

Karam Aboud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.